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1. Introduction  
Collapsing glomerulopathy (CG) is a relatively recently described pattern of renal 
parenchymal injury that is being increasingly recognized as a common cause of end-stage 
renal disease (ESRD) throughout the world (Albaqumi et al., 2006). Although, it is currently 
classified officially as one of the pathological variants of focal segmental glomerulosclerosis 
(FSGS), its defining morphological alterations are in marked contrast to those observed in 
other variants of FSGS. During the initial stages of the disease, the lesion is characterized 
morphologically by an implosive, segmental and/or global wrinkling and retraction of the 
glomerular capillary tufts, pronounced hypertrophy and proliferation of the visceral 
epithelial cells (VECs) or podocytes, and severe tubulointerstitial damage. With disease 
progression, segmental and/or global glomerulosclerosis is also observed in addition to the 
pathognomonic collapsing lesions. Often, both the active and chronic lesions (collapsing and 
sclerotic) co-exist at the time of pathologic diagnosis, hence its classification as a variant of 
FSGS (Albaqumi et al., 2006; Albaqumi & Barisoni, 2006). The exact cause of this mysterious 
lesion is still not known, but a growing list of both genetic and acquired diseases/conditions 
is being reported in association with this morphologic pattern of renal parenchymal injury 
(Albaqumi et al., 2006). The pathogenesis of CG is also still incompletely understood, but 
many advances have been made during the past two to three decades, especially in the 
development and study of animal models of the disease and the discovery of genetic 
abnormalities leading to CG. Various triggering agents typically cause discreet epithelial cell 
injury in different anatomical compartments of the renal parenchyma leading to cell cycle 
dysregulation and a proliferative cellular phenotype (Albaqumi et al., 2006; Albaqumi & 
Barisoni, 2006; Schwimmer et al., 2003). Clinically, CG is characterized by its black racial 
predilection, a high incidence and severity of nephrotic syndrome (NS), a poor response to 
the currently used empirical therapy, and a rapid downhill course to ESRD (Albaqumi & 
Barisoni, 2006; Schwimmer et al., 2003). Although most of the early studies were reported in 
the native kidneys, the disease has also been found more recently to afflict the transplanted 
kidneys, either as a recurrent or de novo disease, frequently leading to loss of the allograft 
(Schwimmer et al., 2003; Canaud et al., 2010; Gupta et al., 2011; Nadasday et al., 2002; Stokes 
et al., 1996; Swaminathan et al., 2006).  Most of the cases have been reported from the 
western countries, but the lesion is also being increasingly recognized in the tropical regions 
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(Kazi & Mubarak, 2007; Mubarak & Kazi, 2010; Nada et al., 2009). The recent increase in the 
reporting of CG partly reflects a genuine increase in the incidence of the disease and partly a 
detection bias resulting from heightened recognition by the pathologists (Albaqumi et al., 
2006). There is no specific treatment for the disorder at present. Newer insights into the 
pathogenesis may pave the pathway for the development of targeted and specific therapy in 
not too distant future (Albaqumi et al., 2006; Albaqumi & Barisoni, 2006).  This chapter 
discusses the nomenclature and historical background, epidemiology, etiology, 
pathogenesis, pathology, clinical manifestations, treatment and the prognosis of the 
condition.  
2. The changing nomenclature of the lesion and the historical background 
The nomenclature of CG has undergone interesting metamorphosis over the time and is still 
controversial. Although, the lesion was first recognized as a distinct clinicopathological 
entity (with a question mark!) in 1986, cases with similar morphology and clinical course in 
the literature trace back to early 1970’s, when they were described as “malignant FSGS” 
(Albaqumi & Barisoni, 2006). During late 1980s and early 1990s, the term CG, was popular 
for this lesion (Weis et al., 1986). However, during mid to late 1990s reports started 
appearing in the literature linking this lesion to the expanding spectrum of FSGS; the main 
reason for this was the clinical presentation and concurrence of sclerotic lesions along with 
collapsing lesions on renal biopsies at the time of pathologic diagnosis (Detwiler et al., 1994; 
Valeri et al., 1996). Indeed, it has been suggested that the morphological lesions of CG may 
represent an early stage in the evolution that eventually are converted into the discrete 
segmental scars typical of FSGS (Detwiler et al., 1994). Another term, “cellular lesion,” was 
also used for this lesion in 1980s (Schwartz & Lewis, 1985). The Columbia classification of 
FSGS officially classified this lesion as a subtype of FSGS (D’Agati et al., 2004). The 
Columbia classification also suggests using “cellular lesion” for a variant of FSGS 
characterized by expansion of the glomerular capillaries by intracapillary hypercellularity, 
in contrast to the intracapillary hypocellularity and collapse of CG. More recent studies 
suggest that the lesion may be distinct from FSGS and merits classification as a separate 
nosologic entity (Meyrier, 1999). Indeed, Barisoni et al. in a recently proposed classification 
of the podocytopathies have categorized CG separately from FSGS and further subdivided it 
into three major subtypes: idiopathic, genetic, and secondary or reactive (Barisoni et al., 
2007). Further studies are needed to clarify this nosologic puzzle. 
3. The magnitude of the problem and the epidemiology 
Although the first report of CG included only six patients, this was soon followed by a series 
of fairly large studies from different centers mostly from United States, and subsequently 
from Europe and more recently from the developing countries (Agarwal et al., 2008; Bariety 
et al., 1998; Deegans et al., 2008; Detwiler et al., 1994; Grcevska & Polenakovik, 1999; Kazi & 
Mubarak, 2007; Laurinavicious et al., 1999; Meyrier, 1999; Mubarak & Kazi, 2010; Nada et 
al., 2009; Valeri et al., 1996; Weis et al., 1986). However, a wide variation is noted in the 
reported frequency of the lesion among all cases of FSGS. The disease thus has a 
cosmopolitan distribution and the wide geographical disparity in the reporting of CG 
appears to be mostly due to detection bias rather than true difference in the prevalence of 
the disorder, as more recently, rates of its diagnosis in both the native and the transplanted 
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kidneys approaching the western studies have been reported (Gupta et al., 2011; Mubarak, 
2011). The increasing reporting of CG in the literature from both the western and the 
developing countries reflects both a true increase in the incidence of the lesion and the 
diagnostic bias (Albaqumi et al., 2006). The increase in the incidence of this lesion has been 
clearly shown in studies from United States and Europe. This lesion constituted 11% of all 
idiopathic FSGS at Columbia Presbyterian Medical Center from 1979 to 1985, 20% from 1986 
to 1989, and 24% from 1990 to 1993 (Valeri et al., 1996). It is interesting to note their first case 
with the typical morphological features of CG was identified in 1979 on retrospective review 
of the renal biopsies, well before the formal recognition of this lesion, and represents the 
first documented case of idiopathic CG in the literature. Even more importantly, this lesion 
comprised 11% of all cases of idiopathic FSGS diagnosed on renal biopsies in pre-
recognition era of CG in their report during the study period from 1979 to 1985 (Valeri et al., 
1996). Another retrospective study by Haas et al. (1995), also from United States, from 1974 
to 1993, identified their first case of CG after 1980, and during the time period of 1980 to 
1993, CG represented 5.3% of cases of idiopathic FSGS in their series. A follow up study by 
the same authors from 1995 to 1997 identified CG in 9% of patients with idiopathic FSGS 
(Haas et al., 1997). Although less common than in the United States, Europe has also not 
lagged behind in the reporting of CG (Meyrier, 1999). The exact cause for the increase in the 
incidence of CG is not known, but may be due to a possible change in the exposure to 
certain infective organisms, chemical agents, or other environmental factors. Similarly, high 
rates of detection have been reported both in native and transplanted kidneys from 
developing countries, but no formal upward trend analysis of CG has been reported from 
developing countries till date (Gupta et al., 2011; Kazi & Mubarak, 2007; Mubarak & Kazi, 
2010; Nada et al., 2009).  
4. The etiology and the associated conditions 
The most common form of CG is the primary or idiopathic one and the exact cause of this, 
as is evident from the name, is still not known. What is apparent from the increased 
reporting of CG is, however, that it is not a single disease but rather a unique pattern of 
renal parenchymal injury, which may result from a multitude of causes (Albaqumi et al., 
2006; Amoura et al. 2006). Indeed, one outcome from the growing awareness of the lesion 
has been the exponential increase in reporting its association with disorders other than 
human immunodeficiency virus (HIV)-1 infection or idiopathic. There are many reports of 
secondary or reactive and genetic causes of this lesion and these provide an insight into the 
widening etiopathogenetic pathways of the condition (Table 1).  
When broadly categorized, these associated disorders fall into seven classes: infections, 
drug toxicity, autoimmune diseases, malignant tumors, genetic diseases, ischemic causes, 
and during the posttransplant period. Among all the known causes/associations, HIV-1 
infection is the most common cause and the disease caused by HIV-1 infection is called 
HIV associated nephropathy (HIVAN) (D’Agati & Appel, 1998). Other infectious agents 
and immunologic derangements are next common reported associations (Albaqumi et al., 
2006). The list of the associated conditions/etiologic agents is growing day by day. As 
alluded to earlier, this wide heterogeneity of the underlying causes/associated conditions 
clearly shows that CG is not a single disease entity, but rather a common final pathway 
resulting from these various insults, all sharing the similar morphologic appearance on 
renal biopsy.  
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One peculiar scenario for the development of CG is the posttransplant period, where the 
disease can occur as recurrent, or more commonly, as de novo disease (Canaud et al., 2010; 
Gupta et al., 2011; Nadasday et al., 2002; Stokes et al., 1996; Swaminathan et al., 2006).   
 
 
Infections 
Human Immunodeficiency Virus-1 infection 
Parvovirus B19 
Cytomegalovirus infection 
Human T cell Lymphotropic Virus-1 
Hepatitis C Virus  
Pulmonary tuberculosis 
Leishmaniasis 
Febrile illness  
 
Autoimmune diseases 
Systemic lupus erythematosus 
Adult Still’s disease 
Mixed connective tissue disorder  
Giant cell arteritis 
Lupus-like syndrome 
 
Malignant tumors 
Multiple myeloma 
Acute monoblastic leukemia  
Hemophagocytic syndrome 
 
Genetic disorders 
Action myoclonus-renal failure syndrome  
Mitochondrial cytopathy 
Familial  
Sickle cell anemia  
 
Drugs/chemotherapeutic agents 
Interferon-α 
Pamidronate  
Cyclosporin A 
 
Post renal and other solid organ transplantation 
Recurrent  
De novo  
Hyaline arteriolopathy  
Acute vascular rejection  
Thrombotic microangiopathy  
 
Table 1. List of known etiologic factors/clinical conditions associated with collapsing FSGS 
in humans.  
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However, the etiological and clinical associations of CG following kidney transplantation 
are still not fully known. Recent studies have implicated ischemia and drug toxicity as  
major predisposing factors in the development of posttransplant CG (Swaminathan et al., 
2006). Recurrent CG provides a unique opportunity to study the evolution of the lesions of 
CG by sequential biopsies with no interference of the confounding secondary causes 
(Bariety et al., 2001). 
5. Pathogenetic mechanisms 
Given the wide range of etiologic associations, a variety of hypotheses for the pathogenesis 
of CG have been proposed over the years, but till date no one definable pathogenic trigger 
has emerged clearly from studying these disparate disorders as a group. However, 
significant advances have been made during past two to three decades in unraveling many 
of the pathways leading to the final common manifestation of the disease. As discussed 
previously in the etiology of the condition, the discovery of secondary and genetic causes of 
CG had been very instrumental in understanding the pathogenesis of the disorder. 
Similarly, the discovery of a number of susceptibility genes for CG in mice and humans, and 
the development of more than a dozen independent mouse models of the disease in 
different centers of the world, represent landmark achievements for studying the disease 
process both in vivo and in a wider perspective (Albaqumi et al., 2006). The mouse models 
can be broadly categorized in to four types based on the nature of the triggering agents. In 
marked contrast to human disease, the pathogenic triggers in each of the four types of 
mouse models of CG are known. These include; HIV-1 gene products, immunoglobulins 
(Ig), oxidative stress, and the disturbance of podocyte paracrine/autocrine regulatory loop 
(Albaqumi et al., 2006). How these different triggering agents lead to the stereotyped 
morphological appearance is still not known. However, a hypothetical “best-fit” model has 
been proposed to explain the final common expression of the disease caused by  
such seemingly divergent initiating stimuli. According to this model, the initiating event 
consists of discreet epithelial cell injury caused by either intrinsic or extrinsic agents 
involving different compartments of renal parenchyma, i.e., both the podocytes and  
the renal tubular epithelium. The injured epithelial cells undergo either apoptosis or 
necrosis, and relay signals to the surrounding un-injured epithelial cells and resident 
immune cells, principally the dendritic cells. Conditioned by the genetic and other 
environmental factors, the surrounding uninjured epithelial cells, subsequently respond 
to the injury, not by the normal repair or regeneration, but in a perverted manner, by the 
processes of dedifferentiation, proliferation and transdifferentiation of, for example, 
podocytes to the macrophage-like phenotype in the glomerular compartment (Albaqumi 
et al., 2006). These phenotypic changes are accompanied by changes in the behavior of 
these cells and their immunophenotypic profile. The immunophenotypic markers of 
maturity are lost, and the markers of immature phenotype, proliferation and macrophage 
lineage are expressed, the latter phenomenon being known as transdifferentiation (Bariety 
et al., 1998) (Table 2).  
The podocytes become cuboidal to epithelioid cell like, lose primary foot processes, and detach 
from the glomerular basement membrane (GBM) and proliferate to form pseudo-crescents. 
Many of these detached podocytes are also passed into the tubules. These phenotypic changes 
result in marked alterations in the normal structure-function relationships of the different 
compartments of the nephron with consequent drastic changes in the function, so 
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characteristic of this disease. The luminal factors and the preexisting disturbance in the 
immune system, coupled with genetic susceptibility, likely contribute to the above sequence of 
events (Albaqumi et al., 2006). Similar changes in tubular epithelium give rise to both acute 
and chronic damage of the tubules, with microcystic transformation of the tubules in many 
forms of CG, especially that induced by HIV-1 infection (Fig. 1).  Although this hypothetical 
“best-fit” model has not been studied directly in humans, but preliminary studies to 
characterize the earliest changes in the development of CG in some mouse models have shown 
that necrosis or apoptosis of epithelial cells occurs before the aberrant proliferation of the 
surviving epithelium. This podocytopenia is transient, short-lived, and not often seen on renal 
biopsies in human CG, and is in contrast with the prominent and pathogenetic podocytopenia 
in non-collapsing FSGS. We have observed this phenomenon in some of our sequential renal 
allograft biopsies done for the investigation of posttransplant proteinuria (unpublished 
observations) (Fig. 1). Indeed, renal allograft represents one of the best models to study the 
evolution and natural history of CG in humans. 
 
 
Fig. 1. Schematic diagram showing a hypothetical “best-fit” model for the pathogenesis of 
collapsing glomerulopathy. According to this model, an intrinsic or extrinsic injurious agent 
discreetly damages some epithelial cells. These cells undergo either apoptosis or necrosis 
and send signals to neighboring epithelial cells and dendritic and other innate immune cells. 
These cells, instead of inducing normal repair or cell cycle arrest upon contact with adjacent 
epithelial cells, cause aberrant hyperplasia of surrounding epithelial cells. These ultimately 
manifest in the form of glomerular collapse and pseudocrescent formation in the glomeruli, 
and in tubular atrophy, microcystic formation in the tubular compartment with interstitial 
inflammation and fibrosis. These structural alterations result in profound disturbances in 
the functions of respective elements of the renal parenchyma.  
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Underexpressed markers  Overexpressed  markers
 
CD10  Cyclin D1
Glomerular epithelial protein 1  Cyclin E
Podocalyxin  Cyclin A
Synaptopodin  Ki-67
Wilms’ tumor-1  Desmin
p27  Cytokeratin
p57  CD68 
Table 2. The main immunohistochemical (IHC) markers of the aberrant podocyte phenotype 
observed in collapsing glomerulopathy. 
Two major common pathways have been proposed to explain the stereotyped response of 
the renal parenchyma to a wide variety of conditions in CG: activation of the immune 
system and the dysregulation of the mitochondrial function ((Albaqumi et al., 2006)) (Fig. 2). 
Many of the diseases associated with CG involve a disturbance of immune homeostasis, 
suggesting at least some role for immune activation in the development of CG. The precise 
immunologic mechanisms are still not completely clear, but studies show that many involve 
T helper type 1 lymphocyte responses, an immune perturbation that already is known to 
aggravate and accelerate other proliferative parenchymal renal diseases, particularly 
crescentic glomerulonephritis (CresGN), the disease that CG mimics most closely on renal 
biopsies.  
The second major common pathway involves some form of acute ischemic insult to the 
kidney such as that resulting from thrombotic microangiopathy (TMA), cyclosporine A 
(CsA) toxicity and severe hyaline arteriopathy ((Albaqumi et al., 2006)). This phenomenon 
has been particularly observed in transplanted kidneys. Recently, three cases of CG have 
been reported in renal allografts on allograft biopsies in association with areas of frank 
segmental infarction (Canaud et al., 2010). We have also observed similar phenomenon on 
renal biopsies from patients with acute cortical necrosis in native kidneys (Kazi & Mubarak, 
2011). Thus, ischemic injury to the glomeruli does have a role in the development of CG. 
This may be mediated by dysregulation of the mitochondrial function and/or altered 
autocrine/paracrine interaction of podocytes, endothelial cells, and/or parietal epithelial 
cells ((Albaqumi et al., 2006)).  
6. Diagnosis and histopathology  
Although the diagnosis of CG may be suspected on clinical grounds, it can only be 
confirmed on the invasive test of renal biopsy. It is diagnosed pathologically by its 
characteristic morphological features in the glomeruli on light microscopy (LM) of renal 
biopsy (Albaqumi et al., 2006; Schwimmer et al., 2003). These consist of focal to diffuse, 
segmental to global, implosive collapse of the glomerular capillary tufts associated with 
marked proliferation and swelling of overlying podocytes (Fig. 3-7). These proliferating 
podocytes form a number of cell layers and fill the Bowman’s space caused by collapsed  
tufts, resulting in the formation of pseudo-crescents, which differ from the true crescents of 
CresGN by their visceral location, the presence of a cleft like space between the pseudo-
crescents and the parietal epithelium, the epithelioid appearance of the cells forming the 
pseudo-crescents, and the absence of fibrin in the pseudo-crescents (Fig. 5, 6). These 
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extracapillary cells lack the spindle cell appearance or pericellular matrix with collagen 
fibers typically noted in true crescents. Another distinguishing feature is that Bowman’s 
capsule itself is intact, without the ruptures typical of cellular crescents of the inflammatory 
type. The proliferating podocytes also exhibit marked cytoplasmic vacuolization and 
prominent, hyaline, protein resorption droplets (Figure 5). There is usually also concurrent 
segmental and/or global glomerulosclerosis at the time of pathologic diagnosis of CG (Fig. 
7). The distribution of lesions may be segmental or global, focal or diffuse and may involve 
any number of the glomeruli (Fig. 4). Due primarily to its poor prognosis among all the 
other variants of FSGS, even a single glomerulus with the characteristic collapsing lesion is 
sufficient for the diagnosis of CG on the biopsy. Although, CG is defined on the basis of 
glomerular lesions, the tubulointerstitial disease is an equally important component of the 
condition and often appears out of proportion to the degree of glomerular sclerosis. 
 
 
Fig. 2. Schematic diagram showing the pathogenesis of collapsing glomerulopathy. As is 
evident from this diagram, several mechanisms are involved in the pathogenesis of CG. A 
variety of triggering agents act through two major common pathways: dysregulation of the 
immune system and mitochondrial dysfunction. Some factors, eg. Infections, can directly 
lead to CG, while others produce lesions of CG by the disturbances in mitochondrial activity 
and immune function.  
It has been suggested that the poor prognosis of the condition results from tubulointerstitial 
pathology rather than glomerular lesions (Meyrier, 1999). The tubulointerstitial component 
shows both acute and chronic changes. These include variable degrees of tubular atrophy, 
interstitial fibrosis, edema, and inflammation, associated with widespread degenerative and 
regenerative changes of the tubular epithelium, including microcyst formation, as shown in 
Fig. 8 and 9. The later are filled with hyaline casts with scalloped margins, as shown in Fig. 
9. It has been proposed that the extent of tubulointerstitial involvement varies depending on 
the etiology of CG and may help in the differential diagnosis of different causes of CG 
(Albaqumi & Barisoni, 2006). 
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Fig. 3. The morphologic evolution of the lesions of collapsing glomerulopathy. A. Medium-
power view showing segmental collapse of capillary tufts. The overlying podocytes have 
not yet markedly proliferated or hypertrophied. They are forming a cobblestone structure 
directly overlying the collapsed tufts. B. Medium-power view showing mild hypertrophy 
and hyperplasia of podocytes overlying the segment of capillary collapse. The 
hypertrophied podocytes are forming a focal crescent-like structure. Many hypertrophied 
podocytes contain protein resorption droplets in their cytoplasm. C. Medium-power view 
showing marked hypertrophy and hyperplasia of podocytes forming a cellular crescent-like 
structure, known as pseudo-crescent. An irregular cleft like space separates the viscerally 
located pseudo-crescent from the Bowman’s capsule. D. Advanced stages of collapsing 
glomerulopathy showing the evolution of collapsed tufts to areas of segmental scar 
formation and adhesion with Bowman’s capsule. Areas of capillary collapse and mild 
hypertrophy of podocytes are still visible.  
 
 
Fig. 4. Low-power photomicrograph showing one glomerulus with global retraction of the 
capillary tufts associated with prominent podocytes arranged as cobblestone-like collar on 
the surface of collapsed capillary tufts. These podocytes have not yet proliferated profusely. 
There is also marked tubulointerstitial involvement with tubular atrophy, microcystic 
dilatation and protein casts in dilated tubules. (Jones’ methenamine silver, ×200) 
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Fig. 5. High power photomicrograph showing global collapse of capillary tufts associated 
with marked hyperplasia and hypertrophy of podocytes. These show prominent 
cytoplasmic vacuolization and numerous hyaline, round to oval, protein resorption droplets 
(arrow). (Jones’ methenamine silver, ×400) 
 
 
Fig. 6. High-power view showing segmental collapse of the capillary tufts associated with 
marked proliferation of the podocytes, forming a pseudo-crescent. The pseudo-crescent is 
separated from the Bowman’s capsule by a cleft like space. There is no fibrinoid necrosis of 
the tuft, which distinguishes it from focal necrotizing lesion. (Jones’ methenamine silver, 
×400)   
As is evident from the above discussion of pathology, the biopsy diagnosis of CG is based 
almost solely on LM study. Immunofluorescence microscopy (IF) for renal panel 
immunoglobulins and complement components is usually negative (Table 3) or shows only 
focal segmental positivity of IgM, C3, and occasionally C1q, in collapsed segments of the 
glomeruli in some cases (Fig. 10). The intensity of staining is usually mild, ranging from 
trace positivity to 1+ but may be up to 2+ on a scale of 0 to 3+.  
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Light microscopic changes 
 
Glomeruli 
Collapse: segmental or global wrinkling and folding of the GBM with 
occlusion or sub-occlusion of the capillary lumena 
Pseudo-crescent formation: podocyte proliferation leading to multiple 
layers of cells located over collapsed tufts 
Swollen podocytes with occasional large nuclei, the later usually in viral 
causes of CG 
Protein reabsorption droplets and vacuolization in the cytoplasm of 
podocytes 
In advanced stages: segmental and/or global sclerosis 
 
Tubulo-interstitial compartment 
 
Acute changes:  
Interstitial edema 
Interstitial inflammation 
Acute tubular injury: flattening of the tubular epithelium, large epithelial 
cells, large, occasionally atypical, nuclei with prominent nucleoli 
 
Chronic changes: 
Tubular atrophy 
Interstitial fibrosis 
Microcysts: dilated, often angulated, tubules with flat epithelium 
containing eosinophilic proteinaceous casts with peripheral scalloping 
 
Vessels 
Nonspecific changes except for CG cases associated with vasculoapathy 
such as thrombotic microangiopathy 
 
Immunofluorescence 
Nonspecific segmental positivity of IgM and C3 in areas of collapse and/or 
sclerosis 
 
Electron microscopy 
Large cuboidal podocytes with pale cytoplasm 
Retraction of primary processes 
Diffuse and severe foot process effacement 
Loss of detectable actin-based cytoskeleton 
Electron dense protein resorption droplets in podocyte cytoplasm 
Detachment of podocytes from underlying GBM and deposition of newly 
formed extracellular matrix in between GBM and podocytes 
Absence of tubulo-reticular inclusions in idiopathic CG. 
Table 3. The characteristic morphologic features of CG observed on renal biopsy 
examination by light microscopy, immunoflourescence, and electron microscopy. 
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Fig. 7. High-power view showing a glomerulus exhibiting an admixture of segmental 
collapse on the left side and segmental scarring with adhesion formation with Bowman’s 
capsule on the right, a not infrequent finding on renal biopsies at the time of primary 
diagnosis. Indeed, this concurrence of sclerotic and collapsing lesions has led the 
investigators to categorize the collapsing glomerulopathy as a variant of focal segmental 
glomerulosclerosis. (Jones’ methenamine silver, ×400) 
The main purpose of IF study is to rule out the secondary causes of CG. Similar to IF, 
electron microscopic (EM) features are also non-specific and consist of wrinkling and 
collapse of GBM in areas of collapse with little or no thickening of GBM. The overlying 
podocytes are greatly hypertrophied with diffuse foot process effacement with focal areas of 
separation from the underlying GBM. No electron dense deposits are observed. EM study 
also helps in excluding secondary causes of CG, such as HIVAN, which reveal characteristic 
tubuloreticular inclusions (D’Agati & Appel, 1998). 
7. Differential diagnosis  
The lesions of full-blown CG are so characteristic that they are rarely mistaken for any other 
renal glomerular diseases. Furthermore, there are very few histopathological lesions on 
renal biopsies which simulate CG and come in the differential diagnosis. These include 
other variants of FSGS as well as other forms of glomerular disease, most notably CresGN. 
Among the variants of FSGS, the closest differential diagnosis of CG is the cellular FSGS. 
Indeed, during 1980s, the term of “cellular lesion” was also used to denote some cases of 
typical CG (Schwartz & Lewis, 1985). Both the collapsing and cellular variants are 
characterized by marked hyperplasia and hypertrophy of podocytes. The discriminating 
features that separate the two variants are the implosive wrinkling and retraction of the 
GBM seen in CG associated with endocapillary hypocellularity as opposed to the expansile 
lesions of endocapillary hypercellularity seen in the cellular FSGS. All other variants of 
FSGS display segmental increase in mesangial matrix with consolidation and the 
obliteration of capillaries (segmental scars), hyalinosis, intracapillary foam cells, and 
adhesion formation with Bowman’s capsule, lesions rarely seen in early stages of CG. 
Advanced cases of CG, however, may display segmental and/or global glomerulosclerosis. 
In many cases of CG, the podocyte proliferation may be so florid as to form a cellular  
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Fig. 8. Medium-power view showing moderate degree of tubular atrophy characterized by 
thickening and wrinkling of the tubular basement membranes, interstitial mononuclear 
inflammatory cell infiltration, and widespread microcystic  transformation of tubules, the 
later filled with proteinaceous casts. The walls of many of the cystically dilated tubules are 
lined by flattened epithelium, which has resulted from degenerative changes. The changes 
in the tubulointerstitial compartment vary from case to case and some authors argue that 
these may be of differential diagnostic value regarding the underlying etiologic condition. It 
is suggested that these tubulointerstitial alterations are more important than the glomerular 
changes of collapsing glomerulopathy from poor prognostic point of view. (Jones’ 
methenamine silver, ×200) 
 
 
Fig. 9. High-power view showing marked tubular atrophy with irregular thickening and 
wrinkling of the tubular basement membranes and reduction in the diameter of the tubules. 
There is also patchy interstitial mononuclear inflammatory cell infiltration, and one tubule, 
which is cystically dilated and  filled with proteinaceous cast with scalloped margins. This 
finding is highly characteristic of some forms of collapsing glomerulopathy. There are also 
marked degenerative changes in some of the tubular epithelial cells with shedding of 
cytoplasm and flattening of the cells (Jones’ methenamine silver, ×400) 
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crescent like structure, known as pseudo-crescent, to differentiate it from true crescents. In 
such cases, the biopsy findings may be misdiagnosed as CresGN. A closer scrutiny of the 
lesions with special attention to the features described previously in pseudo-crescents, along 
with appropriate integration of the clinical history and LM, IF, and EM findings will aid in 
this differential diagnosis (Albaqumi et al., 2006; Schwimmer et al., 2003). 
 
 
Fig. 10. Immunoflourescence on snap-frozen tissue showing segmental positivity of 
immunoglobulin M (IgM) in areas of segmental collapse. C3 also commonly accompanies 
IgM, whereas rest of the renal panel is usually negative. (Fluorescein isothiocyanate (FITC)-
conjugated IgM, , ×200)  
8. The clinical manifestations 
The clinical spectrum of CG is also expanding with the expanding list of associated 
conditions and reflects to some extent the underlying causes. In general, the demographic, 
clinical and laboratory parameters resemble those observed in non-collapsing FSGS, but the 
disease is usually more severe. Idiopathic CG is typically a disease of young adults, with a 
median age of patients being 30 to 40 years, but a wide range of ages have been reported, 
with patients as young as 1.5 years and as old as 82 years.  There are very few reports of CG 
in children (Singh et al., 2000; Gulati et al., 2008). Regarding gender distribution, most 
studies have reported a male predominance, although in one study, females predominated 
over males.  CG is also notorious for its black racial predilection. Since Weiss et al’s original 
report (1986), in which all six patients with CG were black, a predominance of black patients 
in the United States has been noted (Detwiler et al., 1994; Valeri et al., 1996). A study of eight 
patients in France by Bariety et al. also noted a predominance of black patients (1998). A 
review of all published series on CG has shown that, around 50% of the reported cases in the 
literature belong to black race (Albaqumi & Barisoni, 2006).  
On presentation, a majority (>80%) of patients with CG have nephrotic range proteinuria, 
and studies have documented a significantly greater frequency of nephrotic syndrome (NS) 
and higher levels of proteinuria in patients with CG compared with patients with  
non-collapsing FSGS. There is also significantly greater renal functional impairment in 
patients with CG at presentation than patients with non-collapsing FSGS (Schwimmer et al., 
2003). Other severe manifestations of NS are frequent, including hypoalbuminaemia, 
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hypercholesterolemia, and edema, but these manifestations are not significantly different 
from patients with non-collapsing FSGS. Most patients are hypertensive on presentation. 
Once a diagnosis of CG is rendered, the possibility of HIVAN must be ruled out, usually by 
negative HIV serological tests, corroborated by the absence of endothelial tubuloreticular 
inclusions on ultrastructural examination (Mubarak & Kazi, 2010). 
9. Current and future therapeutic approaches  
Currently, there is no specific treatment available for CG, and there are no prospective 
treatment trials of CG (Schwimmer et al., 2003). The therapeutic approaches used at present 
are empirical, and analogous to those used for non-collapsing FSGS, i.e., use of steroids or 
immunosuppressive agents (Albaqumi et al., 2006; Schwimmer et al., 2003). The particular 
therapeutic agents, their dosages, duration, and the definition of response vary among 
different studies, contributing to variable results in different studies. Recent studies in 
patients with non-collapsing FSGS using steroids, cyclosporine, and other 
immunosuppressive agents have shown that remissions were obtained in over 67% of cases, 
resulting in prolonged renal survival (Stirling et al., 2005; Stirling, 2006). In contrast, data 
from retrospective studies of CG suggest that the disease is relatively resistant to most 
immunosuppressive agents (Detwiler et al., 1994; Valeri et al., 1996). Although, variable 
rates of success have been reported, the overall results are poor, with a complete remission 
of 9.6% and a partial remission of 15.2% been reported (Schwimmer et al., 2003). A more 
specific approach involves the use of highly active anti-retroviral therapy (HAART) in cases 
of CG in HIV-1 positive patients. This has been shown to decrease the rate of progression of 
the disease to ESRD by 38% (Albaqumi et al., 2006).  
In view of the present lack of effective therapeutic agents and the uniformly poor prognosis 
of the disease, there is an urgent need for the development of highly effective and targeted 
agents, based on the knowledge of the pathogenetic pathways of CG. Indeed, some progress 
has been made in this regard in animal models. The administration of small molecule 
inhibitors of cyclin-dependent kinases (CDKs) in small animals in preclinical trials has been 
shown to prevent the development, and retard the progression, of experimental lesions of 
CG. In addition, the use of differentiating agents such as retinoic acid derivatives, to inhibit 
the proliferation of podocytes and induce their differentiation to a mature, resting 
phenotype, has also been shown to ameliorate the lesions of experimental CG. Promising 
results have also been obtained in improving renal function in experimental forms of CG by 
the use of small molecule inhibitors of inflammatory pathways controlled by NF-κB and 
cyclooxygenase-2. These findings underscore the multiplicity of pathogenetic pathways for 
the proliferative phenotype of podocytes in CG, and signify the emergence of rational 
approaches to therapy for CG based on the understanding of pathogenesis in the near future 
(Albaqumi et al., 2006).  
10. Natural history and prognosis 
Due primarily to the relatively scant data and the retrospective nature of most studies on 
CG, only generalizations can be made about the natural history of the disease and its 
prognosis. Patients with CG are at high risk of progressing to ESRD. Even with the currently 
available treatment, the incidence of ESRD is 50% to 100% in most series (Agarwal et al., 
2008; Deegans et al., 2008; Detwiler et al., 1994; Grcevska & Polenakovik, 1999; Kazi & 
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Mubarak, 2007; Laurinavicious et al., 1999; Meyrier, 1999; Mubarak & Kazi, 2010; Nada et 
al., 2009; Valeri et al., 1996; Weis et al., 1986). In all comparative studies, the renal survival of 
patients with CG was significantly worse than patients with non-collapsing FSGS. Multiple 
studies have explored the possible prognostic features in CG. Valeri et al. (1996) found that 
progression to ESRD was predicted by serum creatinine concentration at the time of biopsy 
(P < 0.05) and lack of remission of proteinuria (P < 0.025), but did not find a correlation 
between severity of proteinuria or other features of NS with the outcome. The rate of 
progression of renal failure in the collapsing FSGS group correlated highly with the severity 
of tubular degenerative and regenerative changes (P < 0 .02) but not with any other 
parameter of tubulointerstitial or glomerular change. The rate of progression of renal failure 
correlated strongly with male sex. Laurinavicius et al. (1999) reviewed retrospectively the 
data from 42 patients with CG and 18 patients with HIVAN to determine the predictors of 
serum creatinine level, proteinuria, and progression of renal disease. In their multivariate 
model, the risk for ESRD was increased significantly by interstitial fibrosis of >20%, 
creatinine level > 2.0 mg/dL, proteinuria >8 g/d, glomeruli with collapsing lesions >20%, 
and HIV infection (P < 0.0001). Similar to its ominous prognosis in native kidneys, the 
disease also leads to rapidly progressive graft failure, usually with in two years of diagnosis. 
11. Conclusion 
In conclusion, with increasing awareness and research, significant advances have been made 
in understanding the etiopathogenetic mechanisms underlying this mysterious renal 
disease. This is likely to open up the avenues for the development of rational and targeted 
therapy for this uniformly resistant form of disease. The success of preclinical testing of the 
novel therapeutic strategies based on the knowledge of pathogenetic pathways obtained 
from studies in humans and animal models holds promise that the presently poor prognosis 
of CG is likely to improve in the near future. 
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